Article citationsMore>>

Testini, M., Marzaioli, R., Lissidini, G., Lippolis, A., Logoluso, F., Gurrado, A., et al. (2009) The Effectiveness of FloSeal Matrix Hemostatic Agent in Thyroid Surgery: A Prospective, Randomized, Control Study. Langenbeck’s Archives of Surgery, 394, 837-842.
http://dx.doi.org/10.1007/s00423-009-0497-5

has been cited by the following article:

• TITLE: Comparison of an Intraoperative Application of a Haemostatic Agent (PerClot®) with Conventional Haemostatic Procedure after Thyroid Resection

  AUTHORS: Thomas von Ahnen, Martin von Ahnen, Ulrich Wirth, Anna Barisic, Hans Martin Schardey, Stefan Schopf

  KEYWORDS: Hemostatic Agent, Thyroid Resection, Drainage Volume, Post-Operative Hematoma, PerClot®

  JOURNAL NAME: Surgical Science, Vol.6 No.6, June 15, 2015

  ABSTRACT: Background: Postoperative hemorrhage remains an uncommon but potentially life-threatening complication of thyroid surgery. The aim of this case-controlled study was to compare the effectiveness of PerClot® hemostatic agent with hemostasis by conventional technique (HCT) in thyroid surgery. Methods: The thyroid resection was performed from November 2009 to February 2010. Exclusion criteria were applied. There were 30 patients in the HCT group and 30 patients in the PerClot® group. The outcome parameters were postoperative bleeding, the drainage volume 24 hours postoperatively and adverse events according to PerClot®. Results: There was no post-operative hemorrhage in both groups. We found no significant difference between the control andPerClot® group with regard to total drainage volume after 24 h (51 ml ± 36.9 control group/53 ml ± 39.5 PerClot® group (p = 0.79)). There were no adverse events in the PerClot® group. Conclusions: Routine use of PerClot® hemostatic agent has no advantage over conventional hemostasis technique (HCT) in thyroid surgery. In addition, PerClot®is safe and well tolerated.